16 September 2026 editorial review · Item
CARC-101C engineered red blood cells: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: new record; substantive review 16 September 2026.
- Scope and findings: Added named CARC-101C programme. Registry arms explicitly identify engineered red blood cells; no inference from CARC name to CAR-T. Checked single-dose design, target 12 and narrow recent-onset eligibility.
- Primary sources checked: NCT06546436 — study record (registry).
- Limits: Latest registry is August 2024, not yet recruiting despite old estimated primary completion. Current activity and precise payload are unconfirmed; no outcome or availability implied.